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We have previously demonstrated that mitigation of
lethal irradiation by growth hormone is associated with
an increase of insulin-like growth factor 1 (IGF-1) level
in blood, suggesting that IGF-1 may be able to mitigate
against lethal irradiation. In this study, we tested this
possibility directly. BALB/c mice ﬁrst received 7.5 Gy of
total body radiation. Within one hour after irradiation,
the mice were then treated with IGF-1 at a dose of 100
mg/dose, i.v., once a day for 5 consecutive days. In the
saline control group, 2 out of 20 mice (10%) survived
more than 100 days after irradiation. By contrast, 8 out
of 20 mice (40%) in the IGF-1-treated group survived
more than 100 days after irradiation (P < 0.01). A single
dose of IGF-1 (500 mg) given within one hour after
irradiation was as effective as the 5-day dose. IGF-1
remained effective when the treatment was delayed for
at least up to 6 hours post irradiation. Moreover, the
radio-protective effect of IGF-1 was still evident when
higher dose of radiation (8.5 Gy, LD100/30) was used.Similar effects were also observed in a second strain of
mice (C57BL/6). Because hematopoietic system is most
sensitive to total body irradiation, we next sought to
determine the effects of IGF-1 on hematopoietic recovery.
Compared with the saline control group, treatment with
IGF-1 signiﬁcantly accelerated the recovery of both
platelets and red cells in blood in irradiated (7.5 Gy)
BALB/c mice when measured at day +14 post irradiation.
Numbers of total bone marrow cells as well as hemato-
poietic stem cells and progenitors per femur were
signiﬁcantly increased in IGF-1-treated mice compared
with the control group. Using ﬂow cytometric analysis
and a novel single cell assay, we demonstrated that IGF-1
protected both hematopoietic stem cells and progenitors
from radiation-induced apoptosis and cell death. Using
an in vitro culture system, we also demonstrated that
IGF-1 was able to facilitate the proliferation and differ-
entiation of non-irradiated and irradiated hematopoietic
progenitors but not stem cells. These data indicate that
IGF-1 mitigates against lethal irradiation through pro-
tecting hematopoietic stem/progenitor cells from radia-
tion-induced apoptosis and also through enhancing
proliferation and differentiation of surviving hematopoi-
etic progenitor cells.POSTER SESSION 1: IMMUNE RECONSTITUTION173
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Higher absolute lymphocyte count at day 30 (ALC 30)
after allogeniec hematopoietic stem cell transplant (HSCT)
has been associatedwith better overall survival (OS). This has
largely been evaluated in small retrospective studies with
cyclosposrine and methotrexate for graft vs. host disease
(GVHD) prophylaxis. ALC 30 and its impact on patient (pt)
outcomes after tacrolimus (Tac) and mycophenolate mofetil
(MMF) is largely unknown.
We retrospectively evaluated a cohort of 414 consecu-
tive pts between January 2005 and June 2010 at Karmanos
Cancer Center. Patients with GVHD or death before day 30
post transplant were excluded from the analysis (N ¼33).
We performed a multivariate logistic regression analysis to
determine donor/recipient predictors of ALC 30. Cox
proportional hazard models were used to assess the
